Magenta Therapeutics, Inc. Company Review & Valuation MGTA

About Magenta Therapeutics, Inc.

Magenta Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing medicines to bring the curative power of bone marrow transplant to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an ADC program to prevent acute graft and host diseases. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

  • Biotechnology
  • Cambridge, Massachusetts
Primary Stock Exchange Listings

Ticker Symbol:

MGTA

Nasdaq
United States

Stock Price

Performance

Registration required

Please login or create a free account to view all available contents of this section.

Create Account

Health Check

Registration required

Please login or create a free account to view all available contents of this section.

Create Account

Financial Reports

Registration required

Please login or create a free account to view all available contents of this section.

Create Account

Similar Companies

↑ back to top